PRODUCTS & SERVICES
Our capabilities place AAHI at the intersection of emerging sciences, medicine, and the business of biotech, enabling us to provide technologies, services, and insights that advance the state-of-the art for the entire biomedical community.
AAHI provides custom vaccine and immunotherapy solutions with next generation features and functionality, translating into unique products capable of addressing pressing global health needs.

AAHI is uniquely positioned to support development of products based on our immune-enhancing platforms from bench to clinic. Our partnerships with large pharmaceuticals enable collaborations to bring our products to market, providing accessibility around the world.
AAHI PIPELINE
By Platform Technology
AAHI’S ADJUVANT TECHNOLOGY HAS BEEN CLINICALLY TESTED IN NEARLY 10,000 HUMAN VOLUNTEERS AND HAS AN OUTSTANDING SAFETY PROFILE.
By Disease Indication
AAHI’s immune-enhancing platform technologies support vaccine development around the world.
INDICATION | Preclinical | GMP/Tox | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|---|
COVID-19 | Adjuvanted Protein Vaccine (4) | ||||
RNA Vaccine | |||||
Tuberculosis | Adjuvanted Protein Vaccine (2) | ||||
HIV | Adjuvanted Protein Vaccine (9) | ||||
Flavivirus | Bivalent (Zika, yellow fever) | ||||
Pandemic Influenza | Spray-dried | ||||
Bivalent (H7N9, H5N1) | |||||
Malaria | Adjuvanted Protein Vaccine (5) | ||||
Hepatitis C | Adjuvanted Protein Vaccine | ||||
Neglected Tropical Diseases | Hookworm | ||||
Schistosomiasis (2) | |||||
All Adjuvanted Protein Vaccines | Schistosomiasis | ||||
Leprosy |
SERVICES
AAHI offers world-class expertise in the design, formulation, and manufacture of vaccines, adjuvants, immunotherapies, and their components.